Mohamed Kahila, MBBCh
Assistant ProfessorCards
About
Research
Publications
Featured Publications
Pathologic Features of Malignancies Presenting as Asymmetry on Mammography
Kahila M, Chesebro A, Giess C, Rhei E, Hong X, Lester S. Pathologic Features of Malignancies Presenting as Asymmetry on Mammography. Modern Pathology 2024, 37: 100612. PMID: 39265951, DOI: 10.1016/j.modpat.2024.100612.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situCarcinoma in situInvasive carcinomaPathological featuresHigher rate of lymph node metastasisCases of ductal carcinoma in situRate of lymph node metastasisStage III carcinomaTriple-negative carcinomasPathological features of malignancyCases of malignancyFoci of invasionStage III cancerFeatures of malignancyLymph node metastasisRetrospective case seriesTumor growth patternInfiltrative appearanceIII carcinomaHistological typeNeedle biopsyStromal responseIII cancerNode metastasisDesmoplastic responseATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer
Tu X, Kahila M, Zhou Q, Yu J, Kalari K, Wang L, Harmsen W, Yuan J, Boughey J, Goetz M, Sarkaria J, Lou Z, Mutter R. ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer. Molecular Cancer Therapeutics 2018, 17: molcanther.0470.2018. PMID: 30166399, PMCID: PMC6215494, DOI: 10.1158/1535-7163.mct-18-0470.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtaxia Telangiectasia Mutated Proteinscdc25 PhosphatasesCell Cycle CheckpointsCell Line, TumorCheckpoint Kinase 1DNA Breaks, Double-StrandedDrug Resistance, NeoplasmFemaleHomologous RecombinationHumansIsoxazolesMice, Inbred NODMice, SCIDPhosphorylationProteolysisPyrazinesRadiation-Sensitizing AgentsTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysConceptsTriple-negative breast cancerPatient-derived xenograftsTumor-specific radiosensitizationVX-970Breast cancerChemoresistant triple-negative breast cancerResidual triple-negative breast cancerHigh risk of relapseExome sequencingHomologous recombinationHigh riskTriple-negative breast cancer cell linesTriple negative breast cancerBaseline tumor biopsiesNeoadjuvant chemotherapy studyPotential response biomarkersSingle-agent activityAggressive local therapyLocoregional recurrence riskRisk of relapseNegative breast cancerTreatment intensification strategiesATR inhibitor sensitivityBreast epithelial cellsDNA damage signalingPD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, Yin P, Yuan J, Pei H, Li H, Yu J, Song Z, Zhou Q, Zhao F, Liu J, Zhang C, Dong H, Mutter R, Lou Z. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Molecular Cell 2019, 74: 1215-1226.e4. PMID: 31053471, PMCID: PMC6737939, DOI: 10.1016/j.molcel.2019.04.005.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsB7-H1 AntigenBRCA1 ProteinCell Cycle ProteinsCell Line, TumorCisplatinDNA DamageDNA RepairDNA, NeoplasmExosome Multienzyme Ribonuclease ComplexGamma RaysGene Expression Regulation, NeoplasticHCT116 CellsHeLa CellsHumansMARVEL Domain-Containing ProteinsMembrane ProteinsMiceMyelin ProteinsNuclear ProteinsProgrammed Cell Death 1 ReceptorProteolysisRNA StabilityRNA, Small InterferingXenograft Model Antitumor AssaysConceptsIntracellular PD-L1PD-L1Programmed cell death protein 1Cell death protein 1Programmed death-ligand 1Interaction of PD-L1PD-L1 degradationDeath-ligand 1PD-L1 antibodyImmune checkpoint proteinsEfficacy of radiotherapyDNA damage-related genesDNA damage responseInhibition of DNA damage responsePD-L1 bindingB7-H1PD-1RNA exosomeDamage responseMRNA stabilityLigand 1Resistance to DNA damageCellular resistance to DNA damageImmune functionRNA-seq experimentsImage‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, Reis‐Filho J, Ly A, Harms P, Gupta R, Vieth M, Hida A, Kahila M, Kos Z, van Diest P, Verbandt S, Thagaard J, Khiroya R, Abduljabbar K, Haab G, Acs B, Adams S, Almeida J, Alvarado‐Cabrero I, Azmoudeh‐Ardalan F, Badve S, Baharun N, Bellolio E, Bheemaraju V, Blenman K, Fujimoto L, Burgues O, Chardas A, Cheang M, Ciompi F, Cooper L, Coosemans A, Corredor G, Portela F, Deman F, Demaria S, Dudgeon S, Elghazawy M, Fernandez‐Martín C, Fineberg S, Fox S, Giltnane J, Gnjatic S, Gonzalez‐Ericsson P, Grigoriadis A, Halama N, Hanna M, Harbhajanka A, Hart S, Hartman J, Hewitt S, Horlings H, Husain Z, Irshad S, Janssen E, Kataoka T, Kawaguchi K, Khramtsov A, Kiraz U, Kirtani P, Kodach L, Korski K, Akturk G, Scott E, Kovács A, Lænkholm A, Lang‐Schwarz C, Larsimont D, Lennerz J, Lerousseau M, Li X, Madabhushi A, Maley S, Narasimhamurthy V, Marks D, McDonald E, Mehrotra R, Michiels S, Kharidehal D, Minhas F, Mittal S, Moore D, Mushtaq S, Nighat H, Papathomas T, Penault‐Llorca F, Perera R, Pinard C, Pinto‐Cardenas J, Pruneri G, Pusztai L, Rajpoot N, Rapoport B, Rau T, Ribeiro J, Rimm D, Vincent‐Salomon A, Saltz J, Sayed S, Hytopoulos E, Mahon S, Siziopikou K, Sotiriou C, Stenzinger A, Sughayer M, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson E, Tramm T, Tran W, van der Laak J, Verghese G, Viale G, Wahab N, Walter T, Waumans Y, Wen H, Yang W, Yuan Y, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Stovgaard E, Salgado R, Gallagher W, Rahman A. Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer. The Journal Of Pathology 2024, 262: 271-288. PMID: 38230434, PMCID: PMC11288342, DOI: 10.1002/path.6238.Peer-Reviewed Original ResearchConceptsImmune profileInternational Immuno-Oncology Biomarker Working GroupIdentification of clinically relevant biomarkersField of immuno-oncologyBiomarker Working GroupManagement of cancer patientsImmune profiling of tumorsClinical trial perspectiveTranslational implicationsProfiling of tumorsIndividual tumor cellsPredicting disease prognosisClinically relevant biomarkersSubtypes of cancerImmuno-oncologyTumor microenvironmentMultiplex immunohistochemistryTreatment responseTumor cellsBreast cancerTumor samplesCancer patientsTreatment choiceDisease prognosisRelevant biomarkersPitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Thagaard J, Broeckx G, Page D, Jahangir C, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Haab G, Acs B, Akturk G, Almeida J, Alvarado‐Cabrero I, Amgad M, Azmoudeh‐Ardalan F, Badve S, Baharun N, Balslev E, Bellolio E, Bheemaraju V, Blenman K, Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Cheang M, Ciompi F, Cooper L, Coosemans A, Corredor G, Dahl A, Portela F, Deman F, Demaria S, Hansen J, Dudgeon S, Ebstrup T, Elghazawy M, Fernandez‐Martín C, Fox S, Gallagher W, Giltnane J, Gnjatic S, Gonzalez‐Ericsson P, Grigoriadis A, Halama N, Hanna M, Harbhajanka A, Hart S, Hartman J, Hauberg S, Hewitt S, Hida A, Horlings H, Husain Z, Hytopoulos E, Irshad S, Janssen E, Kahila M, Kataoka T, Kawaguchi K, Kharidehal D, Khramtsov A, Kiraz U, Kirtani P, Kodach L, Korski K, Kovács A, Laenkholm A, Lang‐Schwarz C, Larsimont D, Lennerz J, Lerousseau M, Li X, Ly A, Madabhushi A, Maley S, Narasimhamurthy V, Marks D, McDonald E, Mehrotra R, Michiels S, Minhas F, Mittal S, Moore D, Mushtaq S, Nighat H, Papathomas T, Penault‐Llorca F, Perera R, Pinard C, Pinto‐Cardenas J, Pruneri G, Pusztai L, Rahman A, Rajpoot N, Rapoport B, Rau T, Reis‐Filho J, Ribeiro J, Rimm D, Roslind A, Vincent‐Salomon A, Salto‐Tellez M, Saltz J, Sayed S, Scott E, Siziopikou K, Sotiriou C, Stenzinger A, Sughayer M, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson E, Tramm T, Tran W, van der Laak J, van Diest P, Verghese G, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen H, Yang W, Yuan Y, Zin R, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Stovgaard E. Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer. The Journal Of Pathology 2023, 260: 498-513. PMID: 37608772, PMCID: PMC10518802, DOI: 10.1002/path.6155.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesTriple-negative breast cancerBreast cancerTIL assessmentHER2-positive breast cancerRoutine clinical managementTIL evaluationTumor-immune interactionsClinical managementDiscordant assessmentsClinical significancePrognostic biomarkerTIL quantificationCancerDaily practicePatientsTrialsTissue patternsAssessmentLymphocytesBiomarkersSpatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Page D, Broeckx G, Jahangir C, Verbandt S, Gupta R, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Haab G, Acs B, Akturk G, Almeida J, Alvarado‐Cabrero I, Azmoudeh‐Ardalan F, Badve S, Baharun N, Bellolio E, Bheemaraju V, Blenman K, Fujimoto L, Bouchmaa N, Burgues O, Cheang M, Ciompi F, Cooper L, Coosemans A, Corredor G, Portela F, Deman F, Demaria S, Dudgeon S, Elghazawy M, Ely S, Fernandez‐Martín C, Fineberg S, Fox S, Gallagher W, Giltnane J, Gnjatic S, Gonzalez‐Ericsson P, Grigoriadis A, Halama N, Hanna M, Harbhajanka A, Hardas A, Hart S, Hartman J, Hewitt S, Hida A, Horlings H, Husain Z, Hytopoulos E, Irshad S, Janssen E, Kahila M, Kataoka T, Kawaguchi K, Kharidehal D, Khramtsov A, Kiraz U, Kirtani P, Kodach L, Korski K, Kovács A, Laenkholm A, Lang‐Schwarz C, Larsimont D, Lennerz J, Lerousseau M, Li X, Ly A, Madabhushi A, Maley S, Narasimhamurthy V, Marks D, McDonald E, Mehrotra R, Michiels S, Minhas F, Mittal S, Moore D, Mushtaq S, Nighat H, Papathomas T, Penault‐Llorca F, Perera R, Pinard C, Pinto‐Cardenas J, Pruneri G, Pusztai L, Rahman A, Rajpoot N, Rapoport B, Rau T, Reis‐Filho J, Ribeiro J, Rimm D, Vincent‐Salomon A, Salto‐Tellez M, Saltz J, Sayed S, Siziopikou K, Sotiriou C, Stenzinger A, Sughayer M, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson E, Tramm T, Tran W, van der Laak J, van Diest P, Verghese G, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen H, Yang W, Yuan Y, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Stovgaard E. Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer. The Journal Of Pathology 2023, 260: 514-532. PMID: 37608771, PMCID: PMC11288334, DOI: 10.1002/path.6165.Peer-Reviewed Original Research
2026
178 Correlation Between PTEN Protein Expression by Immunohistochemical Staining and PTEN DNA Alterations in Advanced Breast Carcinoma
Matar S, Amraei R, Kahn A, Walther Z, Finberg K, Gibson J, Rozenova K, Kahila M. 178 Correlation Between PTEN Protein Expression by Immunohistochemical Staining and PTEN DNA Alterations in Advanced Breast Carcinoma. Laboratory Investigation 2026, 106: 104457. DOI: 10.1016/j.labinv.2025.104457.Peer-Reviewed Original Research177 Characterization of Frequency and Spectrum of AKT1 and PTEN Alterations in Advanced Breast Cancer
Matar S, Amraei R, Kahn A, Walther Z, Finberg K, Gibson J, Rozenova K, Kahila M. 177 Characterization of Frequency and Spectrum of AKT1 and PTEN Alterations in Advanced Breast Cancer. Laboratory Investigation 2026, 106: 104456. DOI: 10.1016/j.labinv.2025.104456.Peer-Reviewed Original Research1597 Comparative Clinicopathologic and Survival Analysis of Lung Adenocarcinoma, LCNEC, and NSCLC with Neuroendocrine Features
Amraei R, Ragoowansi H, Walther Z, Kahila M, Woodard G, Dacic S. 1597 Comparative Clinicopathologic and Survival Analysis of Lung Adenocarcinoma, LCNEC, and NSCLC with Neuroendocrine Features. Laboratory Investigation 2026, 106: 105899. DOI: 10.1016/j.labinv.2025.105899.Peer-Reviewed Original ResearchQuantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score
He M, Chan N, Liu M, Robbins C, Bates K, Benanto J, Colón-Cartagena L, Kahila M, Zhan H, Krishnamurti U, Moutafi M, Yaghoobi V, Liebler D, Fulton R, Rimm D. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Applied Immunohistochemistry & Molecular Morphology 2026, 34: 143-154. PMID: 41709478, PMCID: PMC13143368, DOI: 10.1097/pai.0000000000001311.Peer-Reviewed Original ResearchTrophoblast cell surface antigen 2Trophoblast cell surface antigen 2 expressionH-scoreBreast cancerQuantitative immunofluorescenceSacituzumab govitecanPathologists' readingsTNBC cohortAntibody-drug conjugate targetsExpression of trophoblast cell surface antigen 2H-score methodSolid tumor typesBreast cancer cohortBreast cancer biopsiesYale-New Haven HospitalBreast cancer samplesCompanion diagnostic testsSurface antigen 2H-score assessmentTumor typesClinical outcomesNew Haven HospitalCancer biopsiesTumor samplesCancer cohort